Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00414-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Jessica R Tait und 13 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: DHAC | National Health and Medical Research Council.
Abstract (Originalsprache)
Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug-resistant hypermutable P. aeruginosa isolates in the hollow-fiber infection model (HFIM). Isolates CW41, CW35, and CW44 (ceftolozane-tazobactam MICs of 4, 4, and 2 mg/L, respectively) from adults with CF were exposed to simulated representative epithelial lining fluid pharmacokinetics of ceftolozane-tazobactam in the HFIM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Victoria, Australia.
- Servicio de Microbiología, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain.
- CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
ORCID-Profile: Marina Harper, Jürgen B Bulitta, John D Boyce, Antonio Oliver, Cornelia B Landersdorfer
Förderung
- DHAC | National Health and Medical Research Council
Zitieren
APA
Tait, J. R., Harper, M., Cortés-Lara, S., Rogers, K. E., López-Causapé, C., Smallman, T. R., Lang, Y., Lee, W. L., Zhou, J., Bulitta, J. B., Nation, R. L., Boyce, J. D., Oliver, A., & Landersdorfer, C. B. (2023). Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00414-23
Vancouver
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, et al. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00414-23
BibTeX
@article{Tait2023,
author = {Tait, Jessica R and Harper, Marina and Cortés-Lara, Sara and Rogers, Kate E and López-Causapé, Carla and Smallman, Thomas R and Lang, Yinzhi and Lee, Wee Leng and Zhou, Jieqiang and Bulitta, Jürgen B and Nation, Roger L and Boyce, John D and Oliver, Antonio and Landersdorfer, Cornelia B},
title = {Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00414-23}
}
EUVIMED